Literature DB >> 5243015

Rubidomycin in acute leukaemia in adults.

J S Malpas, R B Scott.   

Abstract

In a preliminary study rubidomycin was found capable of inducing remission in adults with acute leukaemia, the remission rate in acute myeloblastic leukaemia comparing favourably with that achieved with previous forms of therapy. Marrow aplasia and cardio-toxicity occurred in a number of patients. Supportive measures during the former and early recognition by frequent electrocardiography can do much to mitigate these toxic effects.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5243015      PMCID: PMC1986219          DOI: 10.1136/bmj.3.5612.227

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  2 in total

1.  Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms.

Authors:  G Mathé; M Hayat; L Schwarzenberg; J L Amiel; M Schneider; A Cattan; J R Schlumberger; C Jasmin
Journal:  Lancet       Date:  1967-08-19       Impact factor: 79.321

2.  [Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases].

Authors:  J Bernard; C Jacquillat; M Boiron; Y Najean; M Seligmann; J Tanzer; M Weil; P Lortholary
Journal:  Presse Med       Date:  1967-04-22       Impact factor: 1.228

  2 in total
  16 in total

1.  Inhibition of adriamycin cardiotoxicity by acetyldaunomycin.

Authors:  G Zbinden
Journal:  Experientia       Date:  1975-09-15

Review 2.  Antineoplastic and immunosuppressive drugs. 3. Adverse effects and therapeutic problems.

Authors:  M D Cridland
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 3.  Cancer chemotherapy--the first twenty-five years.

Authors:  R B Scott
Journal:  Br Med J       Date:  1970-10-31

4.  [Clinico-pharmacologic, cytochemical and Feulgen photometric studies in adult undifferentiated cell leukemias under combination chemotherapy with vincristine, daunorubicine and prednisone].

Authors:  P Obrecht; H Merker; H H Hennekeuser; G Meuret; M Westerhausen; A Simon
Journal:  Klin Wochenschr       Date:  1970-11-01

5.  Suppression of adjuvant arthritis by a new cytotoxic compound, rubidomycin.

Authors:  F Quagliata; P M Sanders; D L Gardner
Journal:  Ann Rheum Dis       Date:  1969-03       Impact factor: 19.103

6.  Daunorubicin in acute leukaemia.

Authors:  R L Souhami; T A Prankerd
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

7.  Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.

Authors:  R Ohno; K Kimura; I Amaki; M Hirano; A Hoshino; Y Ikeda; I Kimura; M Kobayashi; K Konno; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 8.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

9.  Adriamycin in the treatment of acute leukaemia.

Authors:  J M Whitehouse; D Crowther; C J Bateman; M E Beard; J S Malpas
Journal:  Br Med J       Date:  1972-02-19

10.  Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases.

Authors:  M F Goodman; M J Bessman; N R Bachur
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.